Nakano Yutaka, Shimane Gaku, Nakamura Kohei, Takamatsu Reika, Aimono Eriko, Yagi Hiroshi, Abe Yuta, Hasegawa Yasushi, Hori Shutaro, Tanaka Masayuki, Masugi Yohei, Kitago Minoru, Nishihara Hiroshi, Kitagawa Yuko
Department of Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
Genomics Unit, Keio University School of Medicine, Tokyo 160-8582, Japan.
Oncol Lett. 2024 Feb 2;27(4):139. doi: 10.3892/ol.2024.14272. eCollection 2024 Apr.
The efficacy of next-generation sequencing (NGS) of tumor-derived DNA from intraoperative peritoneal washing fluid (IPWF) of patients with pancreatic ductal adenocarcinoma (PDAC) who intend to undergo curative resection remains unclear. The aim of the present study was to evaluate whether genomic mutations in tumor-derived DNA from IPWF samples of patients with PDAC who intend to undergo curative resection could be detected using NGS. A total of 12 such patients were included in this study. Cytology of IPWF (CY) was assessed and NGS of genomic tumor-derived DNA from the IPWF was performed to determine whether genomic mutations could be detected in these patient samples. A total of 2 patients (16.7%) had a CY(+) status and 1 patient (8.3%) showed intraoperative macro-peritoneal dissemination; 11 patients underwent radical surgery. Actionable gene alterations were detected in 8 (80.0%) out of the 10 patients with CY(-) status based on NGS of IPWF samples, and 3 (37.5%) patients among those with actionable gene mutations identified from IPWF samples underwent peritoneal dissemination after surgery within ~12 months. The most common genomic mutation was in (9 patients, 75.0%), followed by (3 patients, 25.0%), (1 patient, 8.3%) and (1 patient, 8.3%). These findings indicated that the genomic mutations identified in tumor-derived DNA from IPWF samples of patients with PDAC with a CY(-) status who intend to undergo curative resection are potential biomarkers for predicting the recurrence of early peritoneal dissemination.
对于打算接受根治性切除术的胰腺导管腺癌（PDAC）患者，术中腹腔冲洗液（IPWF）中肿瘤源性DNA的下一代测序（NGS）的疗效尚不清楚。本研究的目的是评估使用NGS能否检测出打算接受根治性切除术的PDAC患者IPWF样本中肿瘤源性DNA的基因组突变。本研究共纳入了12例此类患者。对IPWF进行细胞学检查（CY），并对IPWF中基因组肿瘤源性DNA进行NGS，以确定这些患者样本中是否能检测到基因组突变。共有2例患者（16.7%）CY(+)，1例患者（8.3%）术中出现肉眼可见的腹膜播散；11例患者接受了根治性手术。基于IPWF样本的NGS，在10例CY(-)状态的患者中有8例（80.0%）检测到可操作的基因改变，在IPWF样本中鉴定出具有可操作基因突变的患者中有3例（37.5%）在术后约12个月内出现腹膜播散。最常见的基因组突变是 （9例患者，75.0%），其次是 （3例患者，25.0%）、 （1例患者，8.3%）和 （1例患者，8.3%）。这些发现表明，在打算接受根治性切除术的CY(-)状态的PDAC患者的IPWF样本中，肿瘤源性DNA中鉴定出的基因组突变是预测早期腹膜播散复发的潜在生物标志物。
